These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15647689)

  • 1. PET imaging with F-18 fluorodeoxyglucose for primary lymphoma of bone.
    Park YH; Choi SJ; Ryoo BY; Kim HT
    Clin Nucl Med; 2005 Feb; 30(2):131-4. PubMed ID: 15647689
    [No Abstract]   [Full Text] [Related]  

  • 2. Primary bone lymphoma involving bilateral tibia.
    Giardino AA; Shinagare AB; Shinagare SA; Dewar R; Weckstein D; Mauch P; Ramaiya NH; Freedman AS
    Am J Hematol; 2012 Sep; 87(9):924-5. PubMed ID: 22641233
    [No Abstract]   [Full Text] [Related]  

  • 3. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
    Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis.
    Kawai N; Nishiyama Y; Miyake K; Tamiya T; Nagao S
    Ann Nucl Med; 2005 Dec; 19(8):685-90. PubMed ID: 16444994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).
    Mamot C; Klingbiel D; Hitz F; Renner C; Pabst T; Driessen C; Mey U; Pless M; Bargetzi M; Krasniqi F; Gigli F; Hany T; Samarin A; Biaggi C; Rusterholz C; Dirnhofer S; Zucca E; Martinelli G
    J Clin Oncol; 2015 Aug; 33(23):2523-9. PubMed ID: 26150440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The significance of pre-therapeutic F-18-FDG PET-CT in lymphoma-associated hemophagocytic lymphohistiocytosis when pathological evidence is unavailable.
    Wang J; Wang D; Zhang Q; Duan L; Tian T; Zhang X; Li J; Qiu H
    J Cancer Res Clin Oncol; 2016 Apr; 142(4):859-71. PubMed ID: 26666755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous panniculitis-like T-cell lymphoma with extracutaneous dissemination demonstrated on FDG PET/CT.
    Babb A; Zerizer I; Naresh KN; Macdonald D
    Am J Hematol; 2011 Apr; 86(4):375-6. PubMed ID: 21442643
    [No Abstract]   [Full Text] [Related]  

  • 8. 18F-FDG-PET/CT in lymphoma: two decades of experience.
    Alvarez Páez AM; Nogueiras Alonso JM; Serena Puig A
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):340-9. PubMed ID: 22841459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary hepatic (extranodal) lymphoma: utility of [(18)F]fluorodeoxyglucose-PET/CT.
    Seshadri N; Ananthasivan R; Kavindran R; Srikanth G; Chandra S
    Cancer Imaging; 2010 Oct; 10(1):194-7. PubMed ID: 20926362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma.
    Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T
    Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762
    [No Abstract]   [Full Text] [Related]  

  • 11. 18F-FDG PET/CT in primary non-Hodgkin's lymphoma of the sinonasal tract.
    Tempescul A; Querellou S; Ianotto JC; Boisramé S; Valette G; Berthou C
    Ann Hematol; 2010 Jun; 89(6):635-7. PubMed ID: 19844711
    [No Abstract]   [Full Text] [Related]  

  • 12. Pericardial involvement in a non-Hodgkin lymphoma patient: coregistered FDG-PET and CT imaging.
    Weijs LE; Arsos G; Baarslag HJ; Wittebol S; de Klerk JM
    Eur Heart J; 2007 Nov; 28(22):2698. PubMed ID: 17567624
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone.
    Markova J; Kahraman D; Kobe C; Skopalova M; Mocikova H; Klaskova K; Dedeckova K; Eich HT; Böll B; Dietlein M; Kozak T
    Leuk Lymphoma; 2012 Jan; 53(1):64-70. PubMed ID: 21740300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
    Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
    Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
    J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
    Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
    Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is your diagnosis? Cutaneous B-cell lymphoma.
    Carlson SW; Aneja S; Honda K; Cooper KD
    Cutis; 2014 Nov; 94(5):217, quiz 249-51. PubMed ID: 25474456
    [No Abstract]   [Full Text] [Related]  

  • 19. [18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study.
    Martelli M; Ceriani L; Zucca E; Zinzani PL; Ferreri AJ; Vitolo U; Stelitano C; Brusamolino E; Cabras MG; Rigacci L; Balzarotti M; Salvi F; Montoto S; Lopez-Guillermo A; Finolezzi E; Pileri SA; Davies A; Cavalli F; Giovanella L; Johnson PW
    J Clin Oncol; 2014 Jun; 32(17):1769-75. PubMed ID: 24799481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS.
    Dupuis J; Berriolo-Riedinger A; Julian A; Brice P; Tychyj-Pinel C; Tilly H; Mounier N; Gallamini A; Feugier P; Soubeyran P; Colombat P; Laurent G; Berenger N; Casasnovas RO; Vera P; Paone G; Xerri L; Salles G; Haioun C; Meignan M
    J Clin Oncol; 2012 Dec; 30(35):4317-22. PubMed ID: 23109699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.